CRI
GW Pharma Limited
Application Filed: 2018-01-26
Trademark Application Details
RESPONSE AFTER NON-FINAL ACTION - ENTERED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87771644 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Anessa Owen Kramer |
| Attorney Docket Number | 424640 |
| Law Office Assigned | L90 |
| Employee Name | TARCU, CATHERINE L |
Timeline
| 2018-01-26 | Application Filed |
| 2019-02-05 | Status: Live/Pending |
| 2019-02-11 | Location: TMEG LAW OFFICE 109 |
| 2019-02-11 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  GW Pharma Limited |
| Entity Statement | limited company (ltd.) |
| Address | Sovereign House Histon Cambridge GB CB249BZ |
| Legal Entity Type | |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 36 |
| U.S. Codes: | 100,101,102 |
| International Codes: | 41 |
| U.S. Codes: | 100,101,107 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0421 | Scientific and technological services and research and design relating thereto, namely, scientific research in the field of cannabinoid-based medicines, research on the subject of pharmaceuticals, and pharmaceutical drug development services, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical research and development services all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research, testing and development of pharmaceutical and veterinary preparations all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; biological, clinical and medical research all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; conducting clinical trials for others all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; information, advisory and consultancy services in relation to all of the aforesaid services |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2018-01-30 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-02-07 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2018-05-09 | 3 DOCK D:Assigned to Examiner |
| ASSIGNED TO EXAMINER | 2018-05-10 | 4 DOCK D:Assigned to Examiner |
| ASSIGNED TO EXAMINER | 2018-07-23 | 5 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-07-23 | 6 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2018-07-23 | 7 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-07-23 | 8 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-01-21 | 9 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2019-01-28 | 10 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-02-05 | 11 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-02-05 | 12 TEME I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2019-02-11 | 13 DOCK D:Assigned to Examiner |
| ASSIGNED TO EXAMINER | 2019-03-11 | 14 DOCK D:Assigned to Examiner |
| SUSPENSION LETTER WRITTEN | 2019-04-11 | 15 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2019-04-11 | 16 GNSL S: |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2019-04-11 | 17 GNS3 O:Outgoing Correspondence |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2019-04-17 | 18 ASGN I:Incoming Correspondence |
| REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | 2019-10-11 | 19 RCSC S: |
| LIE CHECKED SUSP - TO ATTY FOR ACTION | 2020-04-20 | 20 RCCK S: |
| REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | 2020-05-06 | 21 RCSC S: |
| REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | 2020-11-23 | 22 RCSC S: |
| ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | 2021-07-28 | 23 ASCK I:Incoming Correspondence |
| LIE CHECKED SUSP - TO ATTY FOR ACTION | 2021-08-18 | 24 RCCK S: |
| NON-FINAL ACTION WRITTEN | 2021-09-15 | 25 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2021-09-15 | 26 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2021-09-15 | 27 GNRN O:Outgoing Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2021-09-15 | 28 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2021-09-15 | 29 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 2021-09-15 | 30 ECDR I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-09-15 | 31 TCCA I:Incoming Correspondence |
| ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | 2022-04-01 | 32 ABN2 O:Outgoing Correspondence |
| ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | 2022-04-01 | 33 MAB2 E:E-Mail |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 